Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
Authors:
Open Access
- 2 August 2011
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 105 (6) , 773-777
Abstract
Background: The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) reverses the O6-methylguanine (O6-meG) lesion induced by dacarbazine. Depletion of MGMT can be achieved using O6-meG pseudosubstrates. Herein, we report the first phase I experience of the novel O6-meG pseudosubstrate lomeguatrib, combined with dacarbazine. Methods: This is a phase I dose-escalation study to determine the maximum tolerated dose and recommended phase II dose (RP2D) of lomeguatrib combined with a single dose of dacarbazine on a 21-day schedule. Results: The vast majority of the 41 patients enrolled had metastatic melanoma (36/41) and most had no previous chemotherapy (30/41). The most frequent non-hematological adverse events (AEs) were nausea (52%), and fatigue (42%). The most frequent AEs of grade 3–4 severity were neutropaenia (42%), leukopaenia (17%), and thrombocytopaenia (12%). Only 1 patient had a partial response and 10 patients had stable disease. Conclusion: The RP2D of lomeguatrib was 40 mg orally twice daily for 10 days combined with 400 mg m−2 of dacarbazine IV on day 2. Oral administration of lomeguatrib substantially increases the haematological toxicity of dacarbazine consistent with experience with other O6-meG pseudosubstrates.Keywords
This publication has 33 references indexed in Scilit:
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcomeBritish Journal of Cancer, 2010
- O6-benzylguanine and BCNU in multiple myeloma: a phase II trialCancer Chemotherapy and Pharmacology, 2007
- Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced MelanomaClinical Cancer Research, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005
- MGMT: its role in cancer aetiology and cancer therapeuticsNature Reviews Cancer, 2004
- Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.Journal of Clinical Oncology, 1998
- Phase I trial of temozolomide using an extended continuous oral schedule.1998
- Prognostic factors in 1,521 melanoma patients with distant metastases.1995
- Intracellular localization of human DNA repair enzyme methylguanine-DNA methyltransferase by antibodies and its importance.1992